Bank of New York Mellon Corp Grows Stake in Heron Therapeutics, Inc. (NASDAQ:HRTX)

Bank of New York Mellon Corp grew its holdings in Heron Therapeutics, Inc. (NASDAQ:HRTXFree Report) by 5.8% in the third quarter, Holdings Channel reports. The firm owned 353,395 shares of the biotechnology company’s stock after buying an additional 19,345 shares during the quarter. Bank of New York Mellon Corp’s holdings in Heron Therapeutics were worth $364,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Point72 Hong Kong Ltd bought a new stake in shares of Heron Therapeutics in the 1st quarter worth $48,000. Bridgefront Capital LLC bought a new stake in shares of Heron Therapeutics in the first quarter worth $60,000. Engineers Gate Manager LP purchased a new position in Heron Therapeutics during the first quarter valued at $73,000. Point72 Middle East FZE purchased a new position in Heron Therapeutics during the fourth quarter valued at $37,000. Finally, Captrust Financial Advisors lifted its position in Heron Therapeutics by 1,539.5% during the second quarter. Captrust Financial Advisors now owns 17,789 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 16,704 shares in the last quarter. Institutional investors own 81.77% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on HRTX shares. StockNews.com upgraded Heron Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, January 16th. Needham & Company LLC lowered their price objective on Heron Therapeutics from $5.00 to $4.00 and set a “buy” rating on the stock in a research report on Wednesday, November 15th.

View Our Latest Stock Analysis on HRTX

Insider Buying and Selling

In related news, EVP William P. Forbes acquired 50,000 shares of Heron Therapeutics stock in a transaction on Thursday, November 16th. The shares were bought at an average cost of $0.94 per share, with a total value of $47,000.00. Following the completion of the purchase, the executive vice president now directly owns 54,000 shares of the company’s stock, valued at approximately $50,760. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In related news, EVP William P. Forbes acquired 50,000 shares of Heron Therapeutics stock in a transaction on Thursday, November 16th. The shares were bought at an average cost of $0.94 per share, with a total value of $47,000.00. Following the completion of the purchase, the executive vice president now directly owns 54,000 shares of the company’s stock, valued at approximately $50,760. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Ira Duarte acquired 85,000 shares of Heron Therapeutics stock in a transaction on Thursday, November 16th. The shares were bought at an average cost of $0.89 per share, for a total transaction of $75,650.00. Following the completion of the purchase, the chief financial officer now directly owns 85,000 shares of the company’s stock, valued at $75,650. The disclosure for this purchase can be found here. Over the last three months, insiders have bought 285,000 shares of company stock worth $260,650. Corporate insiders own 6.40% of the company’s stock.

Heron Therapeutics Trading Up 8.2 %

NASDAQ:HRTX opened at $2.63 on Tuesday. The company has a market capitalization of $394.68 million, a P/E ratio of -2.74 and a beta of 1.66. Heron Therapeutics, Inc. has a 12 month low of $0.50 and a 12 month high of $2.95. The business’s 50-day moving average is $2.02 and its 200 day moving average is $1.47.

Heron Therapeutics (NASDAQ:HRTXGet Free Report) last posted its earnings results on Tuesday, November 14th. The biotechnology company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.14. The firm had revenue of $31.43 million during the quarter, compared to analysts’ expectations of $31.63 million. On average, research analysts forecast that Heron Therapeutics, Inc. will post -0.9 earnings per share for the current year.

Heron Therapeutics Company Profile

(Free Report)

Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Further Reading

Want to see what other hedge funds are holding HRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heron Therapeutics, Inc. (NASDAQ:HRTXFree Report).

Institutional Ownership by Quarter for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.